NCT05042375 2022-11-17
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
Clinical Trials
7 trialsNCT05049681 2021-09-20
Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell
The First Affiliated Hospital of Zhengzhou University
Phase 3 Unknown
NCT04426955 2021-09-16
Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT03668496 2021-03-15
A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT04768075 2021-02-24
Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC
Guangdong Association of Clinical Trials
Phase 3 Unknown
NCT04404491 2020-05-27
Clinical Control Study of Immunotherapy and Concurrent Chemoradiotherapy in Patients With Esophageal Cancer Recurrence
The First Affiliated Hospital of Henan University of Science and Technology
Phase 3 Unknown
NCT04203485 2020-05-08
Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown